Margin Headwinds Test the Guidance — Zydus Q1 in Focus

Zydus Lifesciences enters Q1 FY27 on a growth trajectory but faces a margin cliff. Full-year FY26 delivered 16.8% revenue growth to ₹27,148 Cr with EBITDA margins of 31.2%; Q4 alone hit 33.7% EBITDA margin. The company has guided for high-teens revenue growth in FY27 and EBITDA margin above 24% — a substantial step down. The difference: loss of exclusivity (LOE) on high-margin blockbusters Revlimid and Myrbetriq, which are being eroded by generic competition. Zydus also closed the Assertio Holdings acquisition in June 2026 (US specialty pharma, ₹2,700+ Cr), integration costs and depreciation from which will weigh on profitability this year. The USD formulations business has been a growth engine, so execution on integration and offset from new launches will be critical.

A strong Q1 would show: revenue in the ₹7,000+ Cr range (beating seasonal lightness); EBITDA margin at or above 25% (demonstrating that non-Revlimid segments can offset LOE); US formulations (now including Assertio) growing mid-to-high teens YoY; and guidance reiteration or confidence on FY27 margin floor. A weak Q1 would be: revenue miss below ₹6,800 Cr; EBITDA margin below 24%; margin beat driven entirely by cost-cutting (not organic); or forward guidance reduced due to unforeseen headwinds (supply disruptions from July flooding, Baddi facility FDA warning letter, or Assertio integration delays). Watch for any update on the Sterling API acquisition closing date (originally Dec 2024, deferred to Sep 2026) — further slippage would signal execution risk.

The events scan shows business momentum mixed with regulatory and operational friction. On the positive: Zydus received final USFDA approval for Indocyanine Green Injection (Aug 4), a Phase III nod for Desidustat in Sickle Cell Disease (Jul 23), and a favorable GST appeal decision for its Chhattisgarh subsidiary (Jun 9). The company also signed an MoU with Apollo Hospitals for Shield cancer detection test (Jul 3) and formed a 50:50 JV in Sri Lanka (Jun 26), diversifying the market footprint. On the friction side: temporary facility suspension in Ahmedabad due to heavy rains (Jul 25, now resumed), a ₹108.54 Cr stamp duty demand from Gujarat excise (Jul 29), and a USFDA warning letter for the Baddi facility (Jun 3) regarding talc purity — all minor in isolation but collectively signal execution challenges. Most material: the Assertio acquisition closed on Jun 16, bringing a US-listed specialty pharma with ₹2,700+ Cr enterprise value into the fold; integration costs will depress Q1–Q3 profitability. FII ownership ticked down 11 bps QoQ to 6.95% (FY26 Q4), a subtle signal of caution into the margin-down cycle.